Opinion|Videos|December 23, 2024
The Role of Molecular Testing in Treatment Decisions for NSCLC
This video segment explores the critical role of biomarker testing in identifying patients with ALK-positive NSCLC, discussing the clinical characteristics that guide the use of ALK inhibitors and addressing challenges in implementing comprehensive molecular testing in community settings.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- What characteristics make this patient particularly suitable for treatment with an ALK inhibitor?
- How important is biomarker testing in informing treatment decisions?
- What is your approach to testing and what barriers are there for testing in the community?
Advertisement
Related to this article
Dan Costin, MD, explains the rationale for testing a personalized mRNA vaccine after resection of high-risk stage I NSCLC.
Data from the REZILIENT3 trial support the NDA for zipalertinib plus chemotherapy for those with NSCLC harboring EGFR exon 20 insertion mutations.
Xiuning Le, MD, PhD, discusses the accelerated approval of frontline sevabertinib for patients with HER2-mutated non–small cell lung cancer.
Clinicians must think a lot about how to make testing and novel treatment advances available for patients globally, according to Chul Kim, MD, MPH.
Three nurses discuss the differences in the care and education required for patients with first-line EGFR-mutated non–small cell lung cancer.
Time to worsening of symptoms was improved with amivantamab plus chemotherapy compared with chemotherapy alone in the phase 3 PAPILLON trial.
Advertisement
Advertisement
Trending on CancerNetwork
1
Expanding CAR T and Bispecific Antibody Research in HIV-Associated Lymphoma
2
Why High-Risk Stage I NSCLC Needs a Post-Surgical Vaccine Option
3
How Emory Became the First Adopter of the Liberty Endovascular Robotic System
4
Prioritizing Proton Therapy for Pelvic Nodal Irradiation in Prostate Cancer
5